Literature DB >> 15090586

High dose cyclophosphamide for severe refractory myasthenia gravis.

D E Gladstone, T H Brannagan, R J Schwartzman, A A Prestrud, I Brodsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15090586      PMCID： PMC1763586          DOI： 10.1136/jnnp.2003.019232

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  13 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 2.  High-dose chemotherapy and multiple sclerosis.

Authors:  Daniel Harrison; Douglas E Gladstone
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

3.  Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis.

Authors:  Enrique Gomez-Figueroa; Sofía Garcia-Trejo; Lisette Bazan-Rodriguez; Roberto Cervantes-Uribe; German Chac-Lezama; Juan Carlos López-Hernández; Steven Vargas-Cañas
Journal:  J Neurol       Date:  2019-11-12       Impact factor: 4.849

Review 4.  Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages.

Authors:  Robert A Brodsky; Richard J Jones
Journal:  Autoimmunity       Date:  2008-12       Impact factor: 2.815

5.  Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.

Authors:  Amy E Dezern; Michael J Styler; Daniel B Drachman; Laura K Hummers; Richard J Jones; Robert A Brodsky
Journal:  Am J Blood Res       Date:  2013-01-17

6.  Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.

Authors:  Agnes van Sonderen; Paul W Wirtz; Jan J G M Verschuuren; Maarten J Titulaer
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

7.  Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.

Authors:  Sreenivasa Rao Sudulagunta; Mona Sepehrar; Mahesh Babu Sodalagunta; Aravinda Settikere Nataraju; Shiva Kumar Bangalore Raja; Deepak Sathyanarayana; Siddharth Gummadi; Hemanth Kumar Burra
Journal:  Ger Med Sci       Date:  2016-10-13

8.  Clinical characteristics of refractory myasthenia gravis patients.

Authors:  Joome Suh; Jonathan M Goldstein; Richard J Nowak
Journal:  Yale J Biol Med       Date:  2013-06-13

Review 9.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849

Review 10.  Efficacy and Safety of the TCM Qi-Supplementing Therapy in Patients with Myasthenia Gravis: A Systematic Review and Meta-Analysis.

Authors:  Xi-Qian Yang; Ling Liu; Wen-Yu Yang; Huan-Huan Dong; Yi-Ran Yang; Yun Li
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-03       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.